Clinical Trials Browser

Phase 2/3 × Interventional × Hodgkin Disease × Clear all

Hodgkin Disease, Recurrence

NCT04510610 2020-08-12

Camrelizumab Plus Decitabine in Anti-PD-1 Treatment-naive Patients With Relapsed/Refractory Classical Hodgkin Lymphoma

Phase 2/3 Unknown

100 enrolled

Lymphoid

Hodgkin Disease

NCT00469729 2015-07-10

ExCell

Phase 2/3 Completed

101 enrolled

LymphoidMyeloidOther hematologic neoplasm

Hodgkin Disease, Leukemia, Lymphoid, Lymphoma, Non-Hodgkin, Myelodysplastic Syndromes, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Acute, Hematologic Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT00070187 2013-10-17

Immunotherapy Using Cyclosporine, Interferon Gamma, and Interleukin-2 After High-Dose Myeloablative Chemotherapy With Autologous Stem Cell Transplantation in Treating Patients With Refractory or Relapsed Hodgkin's Lymphoma

Phase 2/3 Completed

24 enrolled

Lymphoid

Hodgkin Disease, Lymphoma, Recurrence

NCT01085058 2010-03-11

CU01

Phase 2/3 Completed

169 enrolled

LymphoidPlasma cell

Hodgkin Disease, Multiple Myeloma

Clinical Trials

Treatment Strategy for Relapsed/Refractory Hodgkin Lymphoma

Camrelizumab Plus Decitabine in Anti-PD-1 Treatment-naive Patients With Relapsed/Refractory Classical Hodgkin Lymphoma

ExCell

Immunotherapy Using Cyclosporine, Interferon Gamma, and Interleukin-2 After High-Dose Myeloablative Chemotherapy With Autologous Stem Cell Transplantation in Treating Patients With Refractory or Relapsed Hodgkin's Lymphoma

CU01